Alleance

Phase 3Small molecule

LLaboratorios Sophia S.A de C.V.

Alleance is one of 16 small molecule programs targeting Myopia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MyopiaRecruiting

MyopiaPhase 3

Recruiting

Competition

Competitive Landscape

20 competitors in Myopia

#DrugCompanyPhaseTrials

Atropen

FFresenius Kabi Taiwan Ltd.

Approved

12 2

Alphagan

Isopto Carpine

Mitosol

Oxylone

1 6

Mydriacyl

FFalcon

Approved

1 7

Lotemax

PPharmos

Approved

1 8

Atropine Sulfate

FFresenius Kabi USA, LLC

Phase 3

3 9

OT-101

OOncotelic Inc.

Phase 3

1 10

Alleance

LLaboratorios Sophia S.A de C.V.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 3Recruiting

Myopia

NCT06389110

Clinical

Trials by Indication[1]

Myopia1 trial

Study to Evaluate the Efficacy of Alleance® (Atropine Sulfate 0.01%) as a Treatment to Delay Myopia and Axial Ocular Elongation in Children.

Recruiting·LLaboratorios Sophia S.A de C.V.·Phase 3·NCT06389110·123 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Alleance. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Alleance compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Alleance. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Laboratorios Sophia S.A de C.V. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: LLaboratorios Sophia S.A de C.V.

Alleance

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Myopia1 trial

References

Drug Info

Quick Facts

Related News